Diabetic autonomic neuropathy;Klinik und diagnose der diabetischen autonomen neuropathie

Fortschritte der Neurologie Psychiatrie

Volumn 69, Issue 9, 2001, Pages 423-438

  Dutsch M ^a   Hilz, M J ^a   Neundorfer B ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTONOMIC NEUROPATHY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; HEART RATE VARIABILITY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PROGNOSIS;

AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETIC NEUROPATHIES; GERMANY; HUMANS;

EID: 0034811646     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16907     Document Type: Article

References (235)

1. The prevalence of autonomic and peripheral neuropathy in insulin-treated diabetic subjects
2. A clinical and histological study on the significance of vascular affections
3. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973
4. Diabetic neuropathy. General review with report of 125 cases
5. Diabetic neuropathy: Prevalence, concordance between clinical and electrophysiological testing and impact of risk factors
6. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy
7. The epidemiology of diabetic neuropathy
8. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers
9. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes
10. Diagnosis, staging and classification of diabetic neuropathy and association with other complications
11. Diabetic autonomic neuropathy
12. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT)
13. Diabetic autonomic neuropathy
14. The epidemiology of diabetic autonomic neuropathy
15. Diabetic autonomic failure
16. Report on the conjoint meetings of the Diabetic Neuropathy Study Group of the EASD (NEUROD1AB) VII and the 4th Diabetic Neumpathy IDF satellite meeting held in Noordwijkerhout, The Netherlands
17. Diabetic and hypoglycemic neuropathy
18. The relationship between peripheral and autonomic neuropathy in insulin-dependent diabetes. A clinical and instrumental evaluation
19. Prevalence and clinical aspects of cardiovascular vegetative neuropathy in a diabetic population
20. The neurology of diabetes
21. Die autonome neuropathie aus neurologischer sicht
22. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics
23. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy
24. Epidemiology of diabetes and its complications
25. The epidemiology of diabetic neumpathy
26. Factors involved in cardiac autonomic neuropathy in diabetic patients
27. The cause of increased pupillary light reflex latencies in diabetic patients: The relationship between pupillary light reflex and visual evoked potential latencies
28. Pupillary signs in diabetic autonomic neuropathy
29. Impact of disease duration on cardiovascular and pupillary autonomic nervous function in IDDM and NIDDM patients
30. Reduced pupillary light reflexes in diabetic autonomic neuropathy
31. Pupil function: Test and disorders
32. Autonomic neural dysfunction in recently diagnosed diabetic subjects
33. Pupillometer for clinical applications using dual 256-element linear CCD arrays
34. Diabetes therapy in advanced age. Managing specific problems
35. Respiratory influence on heart rate in diabetes mellitus
36. Diabetic autonomic neuropathy: Conventional cardiovascular laboratory testing and new developments
37. Cardiac denervation in diabetes
38. Natural history of the diabetic neuropathies
39. Diabetic autonomic neuropathy
40. Analysis of heart rate variability and other noninvasive tests with special reference to diabetes mellitus
41. Diabetic autonomic neuropathy and the heart
42. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy
43. Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients
44. Cardiac autonomic neuropathy and its correlation with QTc dispersion in type 2 diabetes
45. Evaluation of QT interval length, QT dispersion and myocardial m-iodobenzylguanidine uptake in insulin-dependent diabetic patients with and without autonomic neuropathy
46. QTc interval and scintigraphically assessed myocardial perfusion in newly diagnosed and long-term type 1 diabetes mellitus
47. Increased QT dispersion and cardiac adrenergic dysinnervation in diabetic patients with autonomic neuropathy
48. Corrected QT interval in relation to the severity of diabetic autonomic neuropathy
49. The relation between QTc interval prolongation and diabetic complications
50. QT interval prolongation and mortality in type I diabetic patients: A 5-year cohort prospective study
51. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: A meta-analysis
52. Investigation of parasympathetic and sympathetic cardiac innervation in diabetic neuropathy: Heart rate variation versus meta-iodo-benzylguanidine measured by single photon emission computed tomography
53. Effect of glycaemic control on myocardial sympathetic innervation assessed by [1231] metaiodobenzylguanidine scintigraphy: A 4-year prospective study in IDDM patients
54. Use of iodine-123 metaiodobenzylguanidine scintigraphy to assess cardiac sympathetic denervation and the impact of hypertension in patients with non-insulin-dependent diabetes mellitus
55. Diagnosis of cardiovascular autonomic neuropathy in diabetes
56. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up
57. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type 1) diabetes mellitus
58. Reduced myocardial 1231-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients
59. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy
60. Evaluation of cardiac sympathetic nervous function by 1231-metaiodobenzylguanidine scintigraphy in insulin-treated non-insulin dependent diabetics with hypoglycemia unawareness
61. 1231-MIBG myocardial scintigraphy in diabetic patients: Relationship to autonomic neuropathy
62. Myocardial m-[1231]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function
63. The value of cardiovascular autonomic function tests: 10 Years experience in diabetes
64. Hemodynamics in diabetic orthostatic hypotension
65. Abnormal vasoreaction to arousal stimuli - An early sign of diabetic sympathetic neuropathy demonstrated by laser Doppler flowmetry
66. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study
67. Exaggerated orthostatic hypotension as first sign of diabetic autonomic neuropathy in the elderly
68. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy
69. Relationship between splanchnic vasodilation and postprandial hypotension in patients with primary autonomic failure
70. Norepinephrine secretion and production in diabetic autonomic neuropathy
71. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy
72. Prognosis of diabetes mellitus type 1. A follow-up study
73. Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The 'dead in bed' syndrome revisited
74. Changes in the QT interval caused by autonomic cardiovascular involvement in diabetes mellitus
75. Clinical aspects, diagnosis and therapy of diabetic neuropathy
76. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications
77. Autonomic neuropathy: Diagnosis and impact on health in adolescents with diabetes
78. Autonomic neuropathy and the ventilatory responses of diabetics to progressive hypoxemia and hypercarbia
79. High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus
80. Prevalence of unrecognized silent myocardial ischemia and its association with atheroslerotic risk factors in noninsulin-dependent diabetes mellitus
81. Diagnostik und therapie der kardiovaskulären autonomen, diabetischen neuropathie
82. Autonomic neuropathies in diabetes mellitus: Diagnosis - therapy - risks
83. Respiratory muscle function and hypoxic ventilatory control in patients with type I diabetes
84. Cholinergic bronchomotor tone and airway caliber in insulin-dependent diabetes mellitus
85. Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus
86. Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise
87. Clinical presentations of diabetic autonomic failure
88. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (type 2) diabetes mellitus
89. Autonomic dysfunction and the gastrointestinal tract
90. Diabetic autonomic neuropathy
91. Gastric emptying rate and hormonal response in type II diabetics
92. Disorders of gastrointestinal motility associated with diabetes mellitus
93. Gastrointestinal involvement in patients with diabetes mellitus: Part I (first of two parts). Epidemiology, pathophysiology, clinical findings
94. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community
95. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus
96. Autonomic neuropathy: Clinical and instrumental findings
97. Decreased gastric secretory functions in diabetic patients with autonomic neuropathy
98. Small intestinal transit in diabetics
99. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects
100. Correlation between oesophageal dysmotility and cardiovascular autonomic dysfunction in diabetic patients without gastrointestinal symptoms of autonomic neuropathy
101. The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy
102. Upper gastrointestinal involvement in diabetes mellitus: Study of esophagogastric function
103. Oesophageal transit time and cardiovascular autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus
104. Abnormal gastric and small intestinal motor function in diabetes mellitus
105. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum)
106. Reduced gastric emptying and mesenteric blood flow in IDDM with cardiac autonomic neuropathy
107. Gastric emptying in diabetes mellitus: Relationship to blood-glucose control
108. Slow gastric emptying in type I diabetes: Relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control
109. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus
110. The[13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals
111. The 13C-acetate breath test for the noninvasive assessment of the gastric emptying of a liquid/solid test meal in diabetics
112. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test
113. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: Validation and relationship to gastric symptoms and cardiovascular autonomic function
114. Diabetic gastroparesis from autonomic neuropathy: Surgical considerations and changes in vagus nerve morphology
115. Gastric emptying in patients with type I diabetes mellitus
116. Blood glucose concentration influences postprandial fullness in IDDM
117. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus
118. Domperidone in the management of symptoms of diabetic gastroparesis: Efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial
119. Side-effects of oral erythromycin for treatment of diabetic gastroparesis
120. Evaluation of gastric emptying and motility in diabetic gastroparesis with magnetic resonance imaging: Effects of cisapride
121. Gastrointestinal manifestations of diabetes
122. Colonic dysfunction in diabetes mellitus
123. Gastrointestinal disturbances
124. Studies of the antidiarrheal action of clonidine. Effects on motility and intestinal absorption
125. Treatment of diabetic diarrhea with clonidine
126. Diabetic diarrhea and somatostatin
127. Sensorimotor evaluation of ano-rectal complex in diabetes mellitus
128. Abnormalities in gallbladder dynamics of type 1 (insulin-dependent) diabetic patients with autonomic neuropathy
129. Cholecystoparesis with diabetic autonomic neuropathy
130. Gallbladder hypomotility in diabetic polyneuropathy
131. Sonographic study of postprandial gallbladder emptying and common bile duct changes in patients with diabetes or cholelithiasis
132. Impairment of gallbladder emptying in diabetes mellitus
133. Association of diabetes, serum insulin, and C-peptide with gallbladder disease
134. Diabetes and other peripheral neuropathies affecting lower urinary tract function
135. Diagnosis of urinary bladder dysfunction in diabetes mellitus
136. Bladder dysfunction and neuropathy in diabetes
137. Development of urinary bladder dysfunction in diabetes mellitus
138. Investigation and treatment of bladder and sexual dysfunction in diseases affecting the autonomic nervous system
139. Diabetic cystopathy: Relationship to autonomic neuropathy detected by sympathetic skin response
140. Clinical features of diabetic autonomic neuropathy
141. Bladder decompensation correlates with diabetic neuropathy
142. Neurologische erkrankungen
143. Blasenfunktionsstörungen und erektile dysfunktion bei diabetes mellitus
144. Prevalence of self-reported erectile dysfunction in people with long-term IDDM
145. The natural history of impotence in diabetic men
146. Autonomic neuropathy and sexual impotence in diabetic patients: Analysis of cardiovascular reflexes
147. Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction
148. Regulation of adrenergic activity in penile corpus cavernosum
149. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence
150. Autonomic regulation of sexual function
151. Retrograde ejaculation in diabetic neuropathy
152. Pilomotor and sudomotor innervation in diabetes
153. Thermoregulatory sweat test
154. Thermoregulatory sweating abnormalities in diabetes mellitus
155. The sweating deficiency in diabetes mellitus: Methods of quantitation and clinical correlation
156. Evaluation of sudomotor function
157. Diabetic anhidrosis
158. Distal small fiber neuropathy: Results of tests of sweating and autonomic cardiovascular reflexes
159. Gustatory sweating in diabetes mellitus
160. Gustatory sweating and diabetes
161. Facial sweating after food: A new sign of diabetic autonomic neuropathy
162. Cardiac autonomic involvement and peripheral nerve function in patients with diabetic neuropathy
163. Untersuchungsmethoden des peripheren autonomen nerven
164. Quantitative sudomotor axon reflex test in normal and neuropathic subjects
165. Quantitative assessment of sudomotor activity by capacitance hygrometry
166. Influence of neuropathy on the microvascular response to local heating in the human diabetic foot
167. NO-dependent smooth muscle vasodilatation is reduced in NIDDM patients with peripheral sensory neuropathy
168. Medial arterial calcification and diabetic neuropathy
169. Correlation of cardiovascular and neuroendocrine tests of autonomic function in diabetes
170. Autonomic neuropathy: Its diagnosis and prognosis
171. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness
172. Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes
173. Hypoglycaemia unawareness in type 1 diabetes: A lower plasma glucose is required to stimulate sympatho-adrenal activation
174. Patients with type 1 diabetes lack vasoconstrictor response in skin microcirculation during insulin-induced hypoglycemia
175. Failure of warning in insulin-induced hypoglycemic reactions
176. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study
177. Lack of glucagon response to hypoglycemia in diabetes: Evidence for an intrinsic pancreatic alpha cell defect
178. Report and recommendation of the San Antonio consensus conference on diabetic neuropathy
179. Early detection of diabetic neuropathy: A neurophysiological study on 100 patients
180. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects
181. The effect of aging on the autonomic nervous system
182. The effect of aging on cardiac autonomic and postganglionic sudomotor function
183. Investigation of autonomic disorders
184. Assessment of cardiovascular autonomic function: Age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses
185. Noninvasive evaluation of heart rate: The time domain
186. Relation of direct assessment of cardiac autonomic function with metaiodobenzylguanidine imaging to heart rate variability in diabetes mellitus
187. Laboratory evaluation of autonomic function
188. Neue aspekte zur kardiovaskulären autonomen diabetischen neuropathie
189. Measurement of heart rate and blood pressure to evaluate disturbances in neurocardiovascular control
190. Maintenance of postural normotension in humans
191. Non-invasive continuous recording of heart rate and blood pressure in the evaluation of neurovascular control
192. Reduced sinus arrhythmia in diabetic autonomic neuropathy
193. Heart rate variability in healthy subjects measured with a bedside computer-based technique
194. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients
195. Analysis of blood pressure and heart rate variability: Theoretical considerations
196. Computer analysis of blood pressure and heart rate variability in subjects with normal and abnormal autonomic cardiovascular control
197. Assessment of autonomic function in humans by heart rate spectral analysis
198. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog
199. Relationship between diabetic autonomic dysfunction and heart rate variability assessed by recurrence plot
200. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
201. Recent advances in the pathogenesis of diabetic neuropathy
202. Experimental diabetic neuropathy: An update
203. Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture
204. Pathologic alterations in the diabetic neuropathies of humans: A review
205. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy
206. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
207. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes
208. Is early diabetic neuropathy a disorder of the dorsal root ganglion? A hypothesis and critique of some current ideas on the etiology of diabetic neuropathy
209. Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus
210. Antibodies to glutamic acid decarboxylase and peripheral nerve function in type 1 diabetes
211. Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: No evidence for an association with autonomic neuropathy
212. Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based cardiac autonomic neuropathy
213. Evidence for specific autoimmunity against sympathetic and parasympathetic nervous tissues in Type 1 diabetes mellitus and the relation to cardiac autonomic dysfunction
214. Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Autonomic brake index and heart-rate variation
215. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dys-innervation in newly diagnosed and long-term IDDM patients
216. Neurotrophins and other growth factors in diabetic neuropathy
217. Diabetic neuropathy, nerve growth factor and other neurotrophic factors
218. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor
219. Regenerating sensory neurones of diabetic rats express reduced levels of mRNA for GAP-43, gamma-preprotachykinin and the nerve growth factor receptors, trkA and p75NGFR
220. Low serum levels of nerve growth factor in diabetic neuropathy
221. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors
222. An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy
223. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years
224. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial
225. Therapie der peripheren diabetischen neuropathie
226. The nerve growth factor 35 years later
227. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
228. Mechanisms and treatment of pain
229. Prognosis in diabetic autonomic neuropathy
230. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics
231. The diagnostic value of the rate-corrected QT interval in long-term type-1 diabetes mellitus
232. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications study
233. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes
234. The natural history of diabetic autonomic neuropathy